The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2
File(s)Manuscript Hartwig et al..pdf (13.91 MB) 1-s2.0-S1097276517300473-main.pdf (4.01 MB)
Accepted version
Published version
Author(s)
Type
Journal Article
Abstract
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is known for specifically killing cancer cells, whereas in resistant cancers, TRAIL/TRAIL-R can promote metastasis via Rac1 and PI3K. It remains unknown, however, whether and to what extent TRAIL/TRAIL-R signaling in cancer cells can affect the immune microenvironment. Here we show that TRAIL-triggered cytokine secretion from TRAIL-resistant cancer cells is FADD dependent and identify the TRAIL-induced secretome to drive monocyte polarization to myeloid-derived suppressor cells (MDSCs) and M2-like macrophages. TRAIL-R suppression in tumor cells impaired CCL2 production and diminished both lung MDSC presence and tumor growth. In accordance, the receptor of CCL2, CCR2, is required to facilitate increased MDSC presence and tumor growth. Finally, TRAIL and CCL2 are co-regulated with MDSC/M2 markers in lung adenocarcinoma patients. Collectively, endogenous TRAIL/TRAIL-R-mediated CCL2 secretion promotes accumulation of tumor-supportive immune cells in the cancer microenvironment, thereby revealing a tumor-supportive immune-modulatory role of the TRAIL/TRAIL-R system in cancer biology.
Date Issued
2017-02-16
Date Acceptance
2017-01-17
Citation
Molecular Cell, 2017, 65 (4), pp.730-742.e5
ISSN
1097-2765
Publisher
Elsevier
Start Page
730
End Page
742.e5
Journal / Book Title
Molecular Cell
Volume
65
Issue
4
Copyright Statement
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
License URL
Sponsor
Biotechnology and Biological Sciences Research Council (BBSRC)
Grant Number
BB/I004580/1
Subjects
Science & Technology
Life Sciences & Biomedicine
Biochemistry & Molecular Biology
Cell Biology
NF-KAPPA-B
CELL LUNG-CANCER
SUPPRESSOR-CELLS
HEPATOCELLULAR-CARCINOMA
CHEMOTHERAPEUTIC DRUGS
TUMORICIDAL ACTIVITY
LIGAND TRAIL
IN-VIVO
EXPRESSION
APOPTOSIS
Publication Status
Published